TACO‐BEL‐3: a feasibility study and a retrospective audit of diuretics for patients receiving blood transfusion at ten hospitals. Issue 4 (26th October 2020)

• Record Type: Journal Article
• Authors: Khandelwal, Aditi; Lin, Yulia; Cserti‐Gazdewich, Christine; Al Moosawi, Muntadhar; Armali, Chantal; Arnold, Donald; Callum, Jeannie; Dallas, Karen L.; Lieberman, Lani; Pavenski, Katerina; Rioux‐Massé, Benjamin; Shehata, Nadine; Shih, Andrew W.; Pendergrast, Jacob
• Is Part Of: Vox sanguinis. Volume 116:Issue 4(2021)
• Page Start: 434
• Page End: 439
• Publication Date: 2020-10-26
• Subjects: furosemide -- randomized clinical trials -- transfusion‐associated circulatory overload; Blood -- Periodicals; Blood -- Transfusion -- Periodicals; Immunohematology -- Periodicals; Immunopathology -- Periodicals; 615.39
• DOI: 10.1111/vox.12994
• Languages: English
• ISSNs: 0042-9007

Abstract

Abstract : Background and Objectives: Transfusion‐associated circulatory overload (TACO) is the leading cause of transfusion‐related morbidity and mortality. A recently completed pilot trial randomized patients to pre‐transfusion furosemide versus placebo but had a slower than expected enrollment rate. We sought to determine whether the lack of recruitment was due to a paucity of eligible patients or excessively restrictive eligibility criteria. Materials and Methods: At 10 sites, eligible patients were retrospectively identified by first screening blood bank databases over one month for all transfusion episodes meeting trial inclusion criteria, defined as non‐surgical patients receiving single RBC unit transfusions. The age threshold was decreased from 65 to 50 years. The first 10 patients meeting inclusion criteria then underwent detailed chart review for the exclusion criteria. The incidence of TACO and furosemide use was also recorded. Results: At the 10 sites, 11 969 red cell units were transfused over 1 month and 1356 met the inclusion criteria. Of the 100 charts reviewed, 60 (60%) had no exclusion criteria. Active bleeding was the most common reason for ineligibility. There were 813 eligible transfusion episodes. Of the eligible patients, 17 (28·3%) had evidence of congestive heart failure, and furosemide was prescribed in 24 (40%). Despite the use of a lower age threshold, three cases of TACO were detected with an incidence of 3%. Conclusion: A large number of transfusion episodes met eligibility criteria. With a 3% incidence of TACO, 50% decrease through the use pre‐transfusion furosemide and a target consent rate of 30%, a definitive trial of approximately 3000 patients could be completed within 1 year.